Sources:
Schmid P, Adams S, Rugo HS, et al. Impassion 130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). ESMO 2018, abstract LBA1_PR.
Schmid P, Adams S, Rugo HS, et al. Impassion 130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). ESMO 2018, abstract LBA1_PR.